Distribution and Prognostic Impact of Oncogenic Drivers in Metastatic Lung Adenocarcinoma : a Retrospective Monocentric Study in Nancy University Hospital Center

Central Hospital, Nancy, France114 enrolled

Overview

The recent discovery of oncogenic drivers has revolutionized the management of advanced lung cancer by development of tyrosine kinase inhibitors targeted therapies. Prevalence of daily tobacco use is evaluated at 31,3 % in Grand-Est region, the only French region with a statistically significative difference for smoking habits. This region shows a higher incidence (+ 13 %) and mortality for lung cancer in comparison to the average for other French regions. The objectives of our studie were to estimate the distribution of oncogenic drivers and analyse their prognostic impacts in the Nancy University Hospital Center metastatic lung adenocarcinoma's population.

Study Type

OBSERVATIONAL

Enrollment

114

Conditions

Adenocarcinoma of Lung Stage IV Adenocarcinoma of Lung, Response to Tyrosine Kinase Inhibitor in, Somatic

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Lung adenocarcinoma * Patients diagnosed at a metastatic stage * Patient who benefited an oncogenic driver research on their histologic samples * Medical follow-up entirely done in Nancy Central Hospital Exclusion Criteria: * Patients with double histology * Synchronous cancer * Patients with surgical care

Locations (1)

Outcomes

Primary Outcomes

Overall survival

Time (in months) from anatomopathological diagnosis to death

Time frame: over a period of 5 years (Day 0 = anatomopathological diagnosis)

Progression Free survival

Time (in months) from anatomopathological diagnosis to progression of the disease assessed by RECIST criteria

Time frame: over a period of 5 years (Day 0 = anatomopathological diagnosis)

Distribution in percentage of main oncogenic drivers in histological samples from metastatic lung adenocarcinoma

Distribution in percentage of main oncogenic drivers (KRAS, EGFR, ALK, ROS-1, BRAS and HER2), assessed by Sanger sequencing or FISH method in histological samples from metastatic lung adenocarcinomas

Time frame: At base line (Day 0 = anatomopathological diagnosis)

Secondary Outcomes

Distribution in percentage of metastasis sites according oncogenic drivers

Distribution in percentage of metastatic sites assessed by CT-scan for metastatic lung adenocarcinomas according oncogenic drivers (KRAS, EGFR, ALK, ROS-1, BRAS and HER2)

Time frame: At baseline (Day 0 = anatomopathological diagnosis)